Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study in Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: LY2439821
Drug: Placebo

First Posted Date: 2010-12-03

Last Posted Date: 2016-05-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 32

Registration Number: NCT01253265

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan

A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: LY2216684
Drug: Sertraline

First Posted Date: 2010-12-01

Last Posted Date: 2019-01-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT01250873

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States

LY2189265 and Atorvastatin Interaction Study

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Atorvastatin
Biological: LY2189265

First Posted Date: 2010-12-01

Last Posted Date: 2014-10-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 27

Registration Number: NCT01250834

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom

A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women

Phase 1

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: LY333334
Drug: Placebo

First Posted Date: 2010-11-30

Last Posted Date: 2012-10-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 251

Registration Number: NCT01250145

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, Devon, United Kingdom

A First Human Dose Study to Investigate Safety and Tolerability of LY2979165 in Healthy Volunteers

Phase 1

Completed

Conditions: Bipolar Disorder

Interventions: Drug: LY2979165
Drug: Placebo

First Posted Date: 2010-11-25

Last Posted Date: 2011-06-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 25

Registration Number: NCT01248052

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Singapore, Singapore

A Study of LY2157299 in Participants With Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: LY2157299
Drug: Sorafenib
Drug: Ramucirumab

First Posted Date: 2010-11-24

Last Posted Date: 2021-01-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 204

Registration Number: NCT01246986

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 9 locations

A Study of LY3009104(Baricitinib) for Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: LY3009104
Drug: Placebo

First Posted Date: 2010-11-24

Last Posted Date: 2018-04-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 34

Registration Number: NCT01247350

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Stomach Cancer

Interventions: Biological: Ramucirumab
Drug: Placebo
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5-Fluorouracil

First Posted Date: 2010-11-24

Last Posted Date: 2014-10-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 168

Registration Number: NCT01246960

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marshfield, Wisconsin, United States

A Study of LY2608204 in Patients With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY2608204

First Posted Date: 2010-11-24

Last Posted Date: 2018-11-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT01247363

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore

A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: LY2216684
Drug: Fluoxetine

First Posted Date: 2010-11-19

Last Posted Date: 2019-01-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT01243957

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Evansville, Indiana, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy